Pfizer
From family gatherings and seasonal celebrations, to work events and caring commitments, no one wants COVID-19 to get in the way of their daily lives.
Pfizer and BioNTech’s ‘Lots To Do’ campaign highlights the modern lifestyle demands that many customers face, focusing on the need for convenient, private COVID-19 vaccination options for adults who are not eligible on the NHS.
As a pharmacist, you’re well positioned to provide this service and make private COVID-19 vaccinations available within your community.
Designed with busy pharmacists in mind
Pfizer and BioNTech’s COMIRNATY KP.2 is available to community pharmacists looking to add private COVID-19 vaccinations to their revenue stream. This is aimed at anyone who would like to purchase a COVID-19 vaccine privately who is not covered by the National Immunisation Programme.
The single-dose COMIRNATY KP.2 pre-filled syringes offer advantages tailored to pharmacy operations:
- No need to draw up from a vial into a syringe1
- COMIRNATY KP.2 pre-filled syringe is a self-contained product with one dose per syringe, creating potential stock efficiencies1,2
- With twice-daily delivery services via Alliance Healthcare (Monday to Friday — Saturday deliveries are available in some locations) and clear order cut-off times, pharmacists can easily manage stock and order with confidence, maintaining flexibility based on local demand3,4
Helping customers with ‘Lots To Do’
COVID-19 may not be the worrying threat it once was for most, but for people balancing packed schedules, it may still be a concern. COMIRNATY KP.2 helps your customers try and reduce disruption caused by the illness.
Interested in offering COMIRNATY?
Click here for more information about private supply of Pfizer COVID-19 vaccines.
COMIRNATY COVID-19 mRNA Vaccines, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.
Prescribing Information for COMIRNATY®▼ vaccines, available for use in the private market, can be found here.
For more information about COMIRNATY® KP.2▼, please visit PfizerPro.
Special warnings1
Hypersensitivity and anaphylaxis
- Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
- Close observation for at least 15 minutes is recommended following vaccination. No further dose of the vaccine should be given to those who have experienced anaphylaxis after a prior dose of COMIRNATY.
Myocarditis and pericarditis
- There is an increased risk of myocarditis and pericarditis following vaccination with COMIRNATY. These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Available data indicate that most cases recover. Some cases required intensive care support and fatal cases have been observed.
- Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis. Vaccinees (including parents or caregivers) should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis such as (acute and persisting) chest pain, shortness of breath, or palpitations following vaccination.
- Healthcare professionals should consult guidance and/or specialists to diagnose and treat this condition.
For the most up to date safety profile information and guidance on the management of treatment related adverse events, please refer to the full Summary of Product Characteristics for COMIRNATY KP.2, available here.
Adverse events reporting
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via a Yellow card. Reporting forms and information can be found at: coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.
Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.
PP-CMR-GBR-0839 / April 2025
- 1.Summary of Product Characteristics: COMIRNATY® KP.2 30 microgram/dose dispersion for injection, glass pre-filled syringe COVID-19 mRNA Vaccine. . Accessed April 2025. https://www.medicines.org.uk/emc/product/100164/smpc
- 2.Larochelle E, Verdonck O, Fortier LP, Richebe P. Atropine waste in operating rooms. How can prefilled syringes prevent this? Presented at the 2018 Annual Meeting of the Canadian Anesthesiologists’ Society. 2018;2018:S53.
- 3.A guide to Alliance Healthcare. Alliance Healthcare. Accessed April 2025. https://www.alliance-healthcare.co.uk/sites/g/files/xpfdlm151/files/2020-09/A%20guide%20to%20Alliance%20Healthcare_2020_06%20-%20FINAL%2015.09.20.pdf
- 4.Handling complex wholesale distribution requirements. Alliance Healthcare. Accessed April 2025. https://www.alliance-healthcare.co.uk/pharmacy-solutions/wholesale-distributors
You may also be interested in
A shrinking world: What the COVID-19 pandemic taught us about travel vaccines in a globalised society
Sponsored feature
Smoking cessation drug could help young people quit vaping, study results suggest
